Brief: Medincell FY Operating Loss At EUR 21 Mln

Medincell SA

10/06/2024 07:10

June 10 (Reuters) - Medincell SA  MEDCL.PA :
    * SALES RAMP-UP IN LINE WITH FORECASTS: $80 MILLION IN
REVENUE
ANTICIPATED BY TEVA IN 2024
    * FY OPERATING LOSS EUR 21.0 MILLION, A 13% IMPROVEMENT
VERSUS
PREVIOUS YEAR
    * FY CLOSING CASH POSITION: EUR 19.5 MILLION (OF WHICH EUR
5.2
MILLION IN FORM OF NON-RISKY FINANCIAL ASSETS)
    * ACCELERATION OF PHASE 3 CLINICAL TRIAL OF MDC-TJK
(OLANZAPINE,
SCHIZOPHRENIA), SECOND ANTIPSYCHOTIC DEVELOPED WITH TEVA
    * END OF RECRUITMENT IN JANUARY 2024, 9 MONTHS EARLIER THAN
ORIGINALLY PLANNED
    * END OF PHASE 3 CLINICAL TRIAL OF MDC-CWM: RECRUITMENT OF
151
PATIENTS COMPLETED IN AUGUST 2023

Source text for Workspace:  urn:newsml:reuters.com:*:nBwBH1mYa
Further company coverage:  MEDCL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))